Cuba reported today 2,987 new COVID-19 cases, 3,074 hospital discharges and three fatalities.

Over 400,000 booster doses of the Cuban vaccine Abdala, the first of its kind authorized in Latin America for emergency use, have already been administered in the province of Holguin as part of the anti-COVID-19 immunization campaign and the control of the disease during the new normal.

A clinical trial of viral neutralization at the Pedro Kourí Institute of Tropical Medicine (IPK) showed that the COVID-19 vaccines Abdala and Soberana are effective against the omicron variant of virus.

Cuban scientists expressed their willingness to expand the local production of COVID-19 vaccines for the sake of collaboration among the nations towards the world immunization against the coronavirus.

A total of 9,801,366 people in Cuba have completed the COVID-19 vaccination program, with the vaccines developed in the country, Soberana 02, Soberana Plus and Abdala.

Cuba is working on a clinical study with the anti-COVID-19 Abdala vaccine in children under two years of age, the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym) reported today on Twitter.

Cuba studied a total of 25,369 samples for surveillance during the day, resulting positive 2,764. The country accumulates 12,520,458 samples taken and 1,028,183 positive.

A new solidarity shipment from Russia arrived in Havana with medical supplies for the Cuban health system, amounting to two million dollars.

The spread of the SARS-Cov-2 variant Omicron has increased contagion in the country with a steady increase of COVID-19 positive cases and hospitalizations over the past six weeks, said Cuban Health Minister Jose Angel Portal as he analyzed the country’s epidemiological scenario.

The Provincial Center of Electromedicine in Holguin promotes a group of innovations to maintain the vitality of equipment and diagnostic equipment in the public health sector in the midst of COVID-19, as part of the programs prioritized within this branch in Cuba.

Bahamian health authorities welcomed today the Cuban medical brigade of the Henry Reeve contingent, which begins its support work in the confrontation with the COVID-19.

Cuba studied a total of 31,516 samples for surveillance during the day, with 3,307 positive results. The country accumulates 12, 495,089 samples taken and 1,025,419 positive.

Cuban president, Miguel Diaz-Canel, highlighted today on Twitter that the vaccine candidate Mambisa, developed at the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym) of the island, is the first in the world of nasal administration that initiates clinical studies in humans.

Rafael Parúas, president of the Cuban Society for the Development of Renewable Energy Sources (FRE) and Environmental Respect (CUBASOLAR) in the province of Guantánamo praised the steps taken in the region to comply with Decree Law 345.